The nurse will monitor for myopathy (muscle pain) when a patient is taking which class of antilipemic drugs?

Choice A reason: Loratadine has no significant advantage in reducing cardiac dysrhythmias compared to diphenhydramine. Both are H1 receptor antagonists, with minimal cardiac effects at therapeutic doses. Older antihistamines like terfenadine had dysrhythmia risks, but loratadine and diphenhydramine are not primarily associated with this issue.

Choice B reason: Loratadine causes minimal gastrointestinal upset, but this is not its primary advantage over diphenhydramine. Both antihistamines have low gastrointestinal side effects, with diphenhydramine’s anticholinergic effects causing more dry mouth. Loratadine’s key benefit is reduced CNS penetration, minimizing sedation.

Choice C reason: Loratadine, a second-generation antihistamine, has less sedative effect than diphenhydramine, a first-generation antihistamine. Its reduced ability to cross the blood-brain barrier minimizes H1 receptor blockade in the CNS, decreasing drowsiness, making it ideal for daytime use in allergic conditions.

Choice D reason: Neither loratadine nor diphenhydramine significantly increases bronchodilation. Antihistamines block histamine-mediated allergic responses, not beta-2 receptors responsible for bronchodilation. Bronchodilation is achieved with beta-agonists like albuterol, making this an incorrect advantage for loratadine over traditional antihistamines.

Choice A reason: Drowsiness is not a common adverse effect of chloroquine, an antimalarial drug. Chloroquine inhibits heme polymerization in Plasmodium, with side effects like visual disturbances or dizziness. Drowsiness is more associated with antihistamines or CNS depressants, not chloroquine’s mechanism or pharmacokinetic profile.

Choice B reason: Constipation is not a typical side effect of chloroquine. Its primary adverse effects include gastrointestinal upset, visual toxicity, or neurological symptoms like dizziness. Chloroquine’s action on parasitic metabolism does not significantly affect gastrointestinal motility, making constipation an unlikely reaction to report.

Choice C reason: Dizziness is a known adverse effect of chloroquine, potentially due to its effects on the central nervous system or ototoxicity. Patients should report dizziness, as it may indicate toxicity or neurological involvement, requiring dose adjustment or monitoring to ensure safe antimalarial or anti-inflammatory therapy.

Choice D reason: Insomnia is not a primary adverse effect of chloroquine. While neurological effects like headache or dizziness may occur, insomnia is less common. Chloroquine’s toxicity profile focuses on visual, cardiac, or neurological symptoms, and insomnia is not typically reported, making this less critical to monitor.